Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Prasad Padala to Alzheimer Disease

This is a "connection" page, showing publications Prasad Padala has written about Alzheimer Disease.

 
Connection Strength
 
 
 
4.965
 
  1. Padala PR, Padala KP, Samant RS, James GA. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease. Int Psychogeriatr. 2020 04; 32(4):539-540.
    View in: PubMed
    Score: 0.535
  2. Padala PR, Boozer EM, Lensing SY, Parkes CM, Hunter CR, Dennis RA, Caceda R, Padala KP. Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study. J Alzheimers Dis. 2020; 77(4):1483-1493.
    View in: PubMed
    Score: 0.531
  3. Padala KP, Hunter CR, Parkes CM, Lensing SY, Padala PR. Repetitive Transcranial Magnetic Stimulation Improves Executive Function and Music Rhythm. J Neuropsychiatry Clin Neurosci. 2019 Spring; 31(2):178-180.
    View in: PubMed
    Score: 0.494
  4. Padala PR, Dennis RA, Padala KP. Addressing Possible Effects of Sleep Apnea in a Study of Methylphenidate for Apathy in Alzheimer's Disease: Response to Kolla and Mansukhani. Am J Psychiatry. 2018 08 01; 175(8):792-793.
    View in: PubMed
    Score: 0.481
  5. Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2018 02 01; 175(2):159-168.
    View in: PubMed
    Score: 0.453
  6. Padala PR, Padala KP, Sullivan DH, Reynolds DW, Desouza CV, Potter JF, Burke WJ. Improvement of glycemic control using methylphenidate treatment of apathy: a preliminary report. J Am Geriatr Soc. 2012 Jul; 60(7):1383-4.
    View in: PubMed
    Score: 0.316
  7. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010 Apr; 18(4):371-4.
    View in: PubMed
    Score: 0.270
  8. Zeng L, Perin J, Gross AL, Shade D, Lanct?t KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). Int J Geriatr Psychiatry. 2024 Jun; 39(6):e6108.
    View in: PubMed
    Score: 0.180
  9. Lanct?t KL, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg PB, Shade D, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Padala KP, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. Am J Geriatr Psychiatry. 2023 12; 31(12):1077-1087.
    View in: PubMed
    Score: 0.169
  10. Lanct?t KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2023 11; 35(11):664-672.
    View in: PubMed
    Score: 0.167
  11. Lyketsos CG, Miller DS. Addressing the Alzheimer's disease crisis through better understanding, treatment, and eventual prevention of associated neuropsychiatric syndromes. Alzheimers Dement. 2012 Jan; 8(1):60-4.
    View in: PubMed
    Score: 0.153
  12. Mintzer J, Lanct?t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
    View in: PubMed
    Score: 0.151
  13. Mortby ME, Adler L, Ag?era-Ortiz L, Bateman DR, Brodaty H, Cantillon M, Geda YE, Ismail Z, Lanct?t KL, Marshall GA, Padala PR, Politis A, Rosenberg PB, Siarkos K, Sultzer DL, Theleritis C. Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. Am J Geriatr Psychiatry. 2022 02; 30(2):119-147.
    View in: PubMed
    Score: 0.147
  14. Lanct?t KL, Scherer RW, Li A, Vieira D, Coulibaly H, Rosenberg PB, Herrmann N, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer JE. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
    View in: PubMed
    Score: 0.137
  15. van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanct?t KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
    View in: PubMed
    Score: 0.136
  16. Scherer RW, Drye L, Mintzer J, Lanct?t K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
    View in: PubMed
    Score: 0.116
  17. Padala PR, Padala KP, Lensing SY, Jackson AN, Hunter CR, Parkes CM, Dennis RA, Bopp MM, Caceda R, Mennemeier MS, Roberson PK, Sullivan DH. Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study. Psychiatry Res. 2018 03; 261:312-318.
    View in: PubMed
    Score: 0.116
  18. Padala KP, Padala PR, Lensing SY, Dennis RA, Bopp MM, Roberson PK, Sullivan DH. Home-Based Exercise Program Improves Balance and Fear of Falling in Community-Dwelling Older Adults with Mild Alzheimer's Disease: A Pilot Study. J Alzheimers Dis. 2017; 59(2):565-574.
    View in: PubMed
    Score: 0.108
  19. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):322-33.
    View in: PubMed
    Score: 0.088
  20. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanct?t KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Ballard C, Khin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013 Sep; 9(5):602-8.
    View in: PubMed
    Score: 0.083
  21. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012 Oct; 10(5):296-302.
    View in: PubMed
    Score: 0.080
  22. Sattar SP, Padala PR, McArthur-Miller D, Roccaforte WH, Wengel SP, Burke WJ. Impact of problem alcohol use on patient behavior and caregiver burden in a geriatric assessment clinic. J Geriatr Psychiatry Neurol. 2007 Jun; 20(2):120-7.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.